TY - JOUR AU - ALMEIDA, CRISTINA DE MELO CARDOSO AU - CAMPOS, MARIA ALEXANDRINA DE AU - DEWULF, NATHALIE DE LOURDES SOUZA AU - JUNIOR, PLINIO CEZAR DE ALMEIDA AU - CASCÃO, PAULO CESAR PY - 2019/03/11 Y2 - 2024/03/29 TI - Potential drug interactions in patients with hematologic diseases attended in a public hemotherapy unit of Goias JF - Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde JA - Rev Bras Farm Hosp Serv Saude VL - 8 IS - 2 SE - ARTIGOS PUBLICADOS DO - UR - https://rbfhss.org.br/sbrafh/article/view/285 SP - AB - <p>Objectives: The objective of this study was to describe the incidence of potential drug interactions (DIs) between the prescribed and self-medicated drugs of patients with hematological diseases treated at a public hemotherapy unit.</p><p>Methods: It conducted a cross-sectional analytical quantitative study in patients with hematological diseases in the period from July to November 2014.</p><p>Results: They were interviewed 54 patients aged over 18 years, mostly male, with deficiency of coagulation factors, such as hemophilia and von Willebrand disease, or sickle cell disease, registered and monitored in the Goiás Blood Center. Of the 246 drugs used, 177 were prescribed and 69 self-medication, with an average of 5 drugs per patient and Standard Deviation (SD) of 2.1. It was observed that 88.9% of patients had risk of DIs, with average of 5 DIs per patient (SD=3.6). From the analysis of interactions between drugs, ethanol, tobacco and food were identified 224 potential interactions, presenting the risk factors with significant, adverse reactions associated with drug-drug interactions and self-medication related to drug-tobacco interactions. The class of drugs with greater frequency of use was the hematopoietic group, nervous system and musculoskeletal system, between the last two are the analgesics and anti-inflammatories.</p><p>Conclusion: this study demonstrates the high incidence of potencial DIs in the study group, emphasizing the importance of the pharmacist's role in order to contribute to the multidisciplinary team in the reduction of risks from pharmacotherapy.</p> ER -